Ophthalmic Drugs Market By Prescription Type (Prescription Ophthalmic Drugs, OTC), By Therapeutics (Glaucoma, Retinal Disorder, Dry Eye, Allergic Conjunctivitis) - Growth, Share, Opportunities & Competitive Analysis, 2015 - 2022

Geriatric population is growing with the rising global population, and rising patient base suffering from ocular and eye related disorders has been a major growth driver that have urged the advent of ophthalmic drugs market. In the next few years the demand for ophthalmic drugs is expected to increase significantly in the emerging economies such as China and India. 

The prescription type studied for analyzing the overall ophthalmic drugs market are prescription drugs and over the counter drugs (OTC).  On the basis of therapeutic areas, the global ophthalmic drugs market is segmented into  glaucoma ophthalmic drugs, retinal disorders ophthalmic drugs, dry eye ophthalmic drugs and allergic conjunctivitis. Market size and forecast for each of these segments for the period 2012-2022 are provided in this study along with respective CAGRs for the forecast period 2016-2022.

Geographically, the ophthalmic drugs market is studied for the following regional markets:

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • Russia
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Koreas
  • Rest of Asia-Pacific
• Middle East and Africa
• Latin America
•  

Market size and forecast for these regional and country level markets are presented in this study for the period 2014-2022. Market growth rates for the forecast period 2016-2022 are also included in this report, considering 2015 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global ophthalmic drugs market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global ophthalmic drugs market. This report concludes with company profiles section that highlights major information about the key players engaged in ophthalmic drugs market.

For the purpose of this study, the global ophthalmic drugs market is categorized as follows:

• North America
• Europe
• Asia Pacific
• Latin America (LATAM)
• Middle East and Africa

The geographical segmentation of the global ophthalmic drugs market comprises North America, Europe, Asia-Pacific, Latin America and Middle East and Africa. In base year 2015, North America accounted for the largest market in the ophthalmic drugs market due to the rising number of patient population suffering from ocular diseases in the region. The prevalence of blindness and vision impairment and other eye related disorders is expected to increase rapidly among all age group, gender and racial group in North America. It has been estimated that age related macular degeneration is expected to double by 2050, from 2.1 million to 3.7 million. 

However, factors such as high market saturation, drying pipelines and increasing competition are some of the factors hampering the market potential of North American ophthalmic drug market. Europe is the second largest market for ophthalmic drugs. Better regulatory policies have led to increased trust in the drugs market which is the key factor driving the growth in the Europe market. Asia Pacific ophthalmic drug market holds high growth potential in near future due to factors such as rising geriatric population, rising investments in healthcare infrastructure and increasing prevalence of ocular diseases, which includes disorders of both the cornea and the retina.